Company
Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Cytovia Therapeutics

Main focus: Next-generation iPSC-derived cell therapies

Company stage: Pre-clinical

Diseases (gene editing): Solid tumours, Multiple myeloma

Genome editing tool: TALEN, CRISPR

Funding stage: Private

Location: Aventura, Florida and New York, USA

Website: https://www.cytoviatx.com/

Pipeline: https://www.cytoviatx.com/our-products

Gene editing partnerships: Cellectis

Cytovia Therapeutics is a privately-held biotech company focused on the development of iPSC-derived natural killer (NK)- and CAR-NK cell therapies. The company uses CRISPR as well as TALEN technology, which it has licensed from Cellectis, for genomic editing of its NK cell candidates.

Tags

HashtagCytovia Therapeutics

Company: Cytovia Therapeutics
close
Search CRISPR Medicine